Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 20 Nov 2019 Results published in the Vaccine
- 21 Jun 2018 Status changed from recruiting to completed.
- 12 May 2018 This trial has been completed in Czech Republic (End date: 2018-03-07)